United States: FDA Issues Draft Guidance On Determination Of Reference Product Exclusivity For Biologics

Last Updated: August 8 2014
Article by Colleen Heisey

On August 4, the U.S. Food & Drug Administration ("FDA") issued a draft guidance titled "Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act." The draft guidance is intended to assist biological product sponsors and applicants in submitting appropriate information to FDA to enable a regulatory determination of the "first licensure" date of a reference biological product under section 351(k)(7)(C) of the Public Health Service Act ("PHS Act"), which was added to the Federal Food, Drug, and Cosmetic Act ("FD&C Act") by the Biologics Price Competition and Innovation Act of 2009.

Background

Under section 351(k) of the PHS Act, an application for a biosimilar or interchangeable biologic may not be submitted to FDA until four years after, or approved until 12 years after, first licensure of the reference biologic, respectively referred to as periods of "data exclusivity" and "market exclusivity." An additional six months of "pediatric exclusivity" may be added to the data and market exclusivities if the biologic meets the requirements for pediatric exclusivity under section 505A of the FD&C Act. In addition, seven years of orphan drug exclusivity may be applied if the biologic is indicated for a rare disease or condition under section 527(a) of the FD&C Act, in which case the biologic may not be licensed for that indication until after the expiration of the seven-year orphan drug exclusivity period or the 12-month market exclusivity period, whichever is later.

Process of Determination of "First Licensure" by FDA

Given the significance of data and market exclusivity, the determination under section 351(k) of the date of first licensure of a reference biological product submitted under section 351(a) effectively decides (i) the product's eligibility for various reference product exclusivities and (ii) the lengths of those periods of exclusivity. However, as noted by FDA in the draft guidance, "[m]aking this determination can present unique challenges given the requirements of section 351(k)(7)," which "are made more acute because of the scientific and technical complexities that may be associated with the larger and typically more complex structures of biological products ... as well as the processes by which such biological products are made."

In most cases, the date of first licensure of a reference biological product submitted under section 351(a) will be the initial date the product was licensed by FDA. However, section 351(k)(7)(C) excludes from this determination the date of licensure for the following products:

  • A supplement for the biological product that is the reference product; or
  • A subsequent application filed by the same sponsor or manufacturer of the biological product that is the reference product (or a licensor, predecessor in interest, or other related entity) for:
    • a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength;
    • a modification to the structure of the biological product that does not result in a change in safety, purity, or potency.

As noted by FDA, "because of these exclusions, for each product licensed under section 351(a) of the PHS Act that may serve as a reference product for a biosimilar application, FDA must make a determination regarding the date of first licensure." In its draft guidance, FDA explains how it intends to make these determinations, and provides concrete examples as illustrations of its intended approach.

Identifying a Licensor, Predecessor in Interest, and "Other Related Entity." FDA explained that it "has experience in construing other provisions that require examination of the relationships between business entities." It has construed "predecessor in interest" to include an entity that has been taken over, merged with, or purchased, or has granted exclusive rights to the application or its data. An entity will be considered related if either entity owns, controls, or has the power to own or control the other entity, or the entities are under common ownership or control. FDA will also find parties related when they are or were engaged in commercial collaborations relating to the product's development.

Whether There Has Been a Structural Modification of the Product. FDA explained that in making this determination, it will consider the products' principal structural molecular features and whether they affect the same molecular target. Also, if a sponsor employs a cell line modified from that used to manufacture the previously licensed product, the sponsor would need to first demonstrate the product has been structurally modified, and then show that the modification resulted in a change in safety, purity, or potency.

If So, Whether There Has Been a Change in Safety, Purity, or Potency. FDA explained that this determination "will be made case-by-case" based on supporting evidence submitted by the sponsor. Such evidence may include preclinical or clinical studies, references to the data and information submitted in the 351(a) application of the previously licensed product, and evidence that the change will result in a meaningful benefit to public health when compared to the previously licensed biological product. Also, FDA generally will presume that a structural modification has resulted in a change to the proposed product's safety, purity, or potency if the sponsor demonstrates the product affects a different molecular target than the original product did.

Suggested Information for Submission by Section 351(a) Applicants

FDA concluded by specifying the information a sponsor should include in its 351(a) application, in correspondence related to the application, or in an amendment, depending on the timing and availability of the information during the application process. Specifically, FDA suggested the following information for submission.

  1. A list of all licensed biological products that are structurally related to the biologic being applied for, including those that share some of the principal molecular structural features, target different epitopes of the same target, and share the narrowest target that can be characterized. If a sponsor concludes that no such product has been licensed, it should provide adequate justification for its determination.
  2. For those product listed in item 1 above, a list of those for which the sponsor or any of its affiliates is or was a license holder.
  3. For those products listed in item 2 above, a description of the structural differences from the proposed product, which for protein products should include changes in amino acid sequence; differences due to post-translational events, infidelity of  translation, or transcription; differences in glycosylation patterns or tertiary structure; and differences in biological activities.
  4. For those products listed in item 2 above, evidence of the changes in safety, purity, and/or potency from the proposed product, including how the structural differences relate to these changes.

Comments Should Be Submitted by October 6

To ensure FDA considers comments before issuing the final version of the draft guidance, FDA encourages interested parties to submit comments on the draft guidance by October 6. Comments can be submitted electronically to http://www.regulations.gov [Docket No. FDA-2013-D-1165].

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Colleen Heisey
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions